Affymetrix, a technology developer for technology pharmaceutical, diagnostic, and biotechnology companies, has appointed Timothy Barabe as executive vice president (EVP) and chief financial officer (CFO). Barabe will lead the company’s financial functions as well as the treasury, investor relations, and information technology departments, reporting to Kevin King, president and chief executive officer (CFO). He replaces John Batty, who served three years at Affymetrix and was instrumental in laying the foundation for the company’s long-term growth.
Barabe joins Affymetrix with experience from top-tier pharmaceutical, medical, and emerging life science companies. Since 2006, he served as senior vice president (SVP) and CFO at Human Genome Sciences. Previously, Barabe was CFO at Regent Medical. For more than 20 years, he held senior executive roles in finance, general management, and strategic planning at Novartis, the world’s sixth largest pharmaceutical company. His roles included CFO of the Sandoz Generics Business Unit, president of the CIBA Vision specialty lens business franchise, and group vice president and CFO of CIBA Vision.
Barabe received his MBA in finance from the University of Chicago and his BBA in finance from the University of Massachusetts.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.